SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors brace for an upcoming earnings release, with heavy community speculation focused on the potential for a massive short squeeze given the exceptionally high short interest. Market participants are intensely debating the impact of recent defense contracts and new leadership, creating a highly volatile environment where bulls are aggressively targeting the double-digit price barrier.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing high community engagement ahead of its earnings call, with investors closely watching for updates on revenue growth, government contract progress, and the company's roadmap for 30 logical qubits. Traders are actively debating the company's valuation relative to its quantum sector peers, fueling significant options activity and speculation about potential institutional support.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing high volatility as investors weigh aggressive long-term revenue growth and high-profile partnerships against a significant earnings miss and concerns over valuation. The community remains deeply divided, with many traders capitalizing on the stock's wide swing ranges while others express skepticism regarding the company's hardware sales and the potential impact of upcoming share lock-up expirations.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny and volatility as investors react to a recent analyst downgrade, which cited concerns over a potential revenue headwind in China and broader turnaround struggles. The community is deeply polarized, with many retail participants debating whether the stock is a value trap heading toward the low $30s or an opportunistic long-term entry point following a significant multi-year decline.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing a significant short squeeze following an earnings report that highlighted strong customer prepayments and increased commercial momentum in AI infrastructure. Community discussions are centered on the clash between aggressive retail bulls and high-profile short sellers, as many investors look for continued upside potential amid strong institutional interest and upward price target revisions.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending as investors digest a strong earnings beat and raised full-year guidance fueled by significant AI infrastructure demand, despite some market pushback regarding margin pressures. While some community members voice skepticism about the stock's recent rapid appreciation and valuation, bulls are highlighting the company's critical role in the networking hardware supercycle and ongoing momentum in AI-related product orders.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors weigh the impact of a negative CHMP opinion in Europe against the company's U.S. launch momentum, with active community discussion focusing on the upcoming J-code billing activation, potential NTAP reimbursement, and strategic debt buybacks. Market participants are intensely debating the credibility of long-term milestones, the strength of current commercial sales, and the potential for a future acquisition given the company's de-risked status in the domestic market.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors digest a strong earnings report featuring a significant revenue beat and raised fiscal guidance, fueling optimism around the AI optical infrastructure thesis. While some retail traders are debating the short-term volatility following the announcement, the broader community is actively comparing Coherent's performance to peers like Lumentum and discussing the potential for the stock to reach new all-time highs.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

NBIZ is experiencing extreme volatility as investors debate the sustainability of its underlying asset's growth amid concerns over high-beta AI sector valuations and the inherent decay risks of holding leveraged inverse ETFs. The community is sharply divided, with traders actively scalping the ticker's rapid price swings while others express frustration over the fund's performance relative to its stated leverage objectives.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following positive Q2 earnings results that showcased significant operational improvements, including a narrower Adjusted EBITDA loss and a reaffirmed path to profitability for 2027. Investors are actively discussing the company's strategic $50 million capital raise anchored by the International Finance Corporation, which has largely alleviated liquidity concerns and fueled optimism for the brand's long-term growth trajectory in the African e-commerce sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market capitalization ofread more...

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL)

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL) PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against...

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting...

Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC) Previously Known as Pheton Holdings Ltd. (PTHL) Class Action Lawsuit

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a iTonic Holdings Ltd. (NASDAQ: ITOC)) securities between September 5, 2024 and July 29, 2025 (the "Class...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Bearish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GILDGilead Sciences, Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest GILD News